Clinical utility of chromosome genomic array testing for unclassified and advanced-stage renal cell carcinomas

Nicole Andeen, Xiaoyu Qu, Tatjana Antic, Scott S. Tykodi, Min Fang, Maria S. Tretiakova

Research output: Contribution to journalArticle

Abstract

Context.-Cytogenomic analysis provides a useful adjunct to traditional pathology in the categorization of renal cell carcinomas (RCCs), particularly in morphologically ambiguous cases, but it has disadvantages, including cost. Objective.-To define the clinical scenarios in which this technology has direct clinical applications. Design.-DNA was isolated from paraffin-embedded tissue from 40 selected cases of RCC. Chromosome genomic array testing was performed using the OncoScan. Results.-Of 23 cases of unclassified renal tumors, 19 (83%) were reclassified with incorporation of cytogenetic and histologic features, including 10 as clear cell RCC, 2 as collecting duct carcinoma, 2 as papillary RCC, and 1 as novel TFEB-amplified tumor lacking TFEB translocation. Of 5 tumors with ''hybrid'' oncocytic features, 3 were reclassified as an eosinophilic variant of chromophobe RCC and 1 as oncocytoma. Appropriate staging in 2 patients was determined by identifying distinct, nonshared cytogenetic profiles. Of 11 cases of metastatic clear cell RCC, 7 (63%) had cytogenetic features associated with a poor prognosis. Conclusions.-We identified 5 scenarios in which chromosome genomic array testing has direct clinical utility: (1) to investigate unclassified RCCs, (2) to understand tumors with ''hybrid'' features and ''collision'' tumors, (3) to determine appropriate staging in questions of bilateral tumors and/or metastases, (4) to identify chromosomal aberrations in metastatic clear cell RCCs associated with a worse prognosis, and (5) to identify new entities. This has practical value in our institution, where a molecular profile diagnostically separating morphologically difficult to classify clear cell, papillary, chromophobe, and unclassified RCC influences treatment recommendations and clinical trial eligibility.

Original languageEnglish (US)
Pages (from-to)494-504
Number of pages11
JournalArchives of Pathology and Laboratory Medicine
Volume143
Issue number4
DOIs
StatePublished - Apr 1 2019

Fingerprint

Renal Cell Carcinoma
Chromosomes
Cytogenetics
Neoplasms
Oxyphilic Adenoma
Chromosome Aberrations
Paraffin
Clinical Trials
Pathology
Neoplasm Metastasis
Technology
Kidney
Costs and Cost Analysis
DNA

ASJC Scopus subject areas

  • Pathology and Forensic Medicine
  • Medical Laboratory Technology

Cite this

Clinical utility of chromosome genomic array testing for unclassified and advanced-stage renal cell carcinomas. / Andeen, Nicole; Qu, Xiaoyu; Antic, Tatjana; Tykodi, Scott S.; Fang, Min; Tretiakova, Maria S.

In: Archives of Pathology and Laboratory Medicine, Vol. 143, No. 4, 01.04.2019, p. 494-504.

Research output: Contribution to journalArticle

Andeen, Nicole ; Qu, Xiaoyu ; Antic, Tatjana ; Tykodi, Scott S. ; Fang, Min ; Tretiakova, Maria S. / Clinical utility of chromosome genomic array testing for unclassified and advanced-stage renal cell carcinomas. In: Archives of Pathology and Laboratory Medicine. 2019 ; Vol. 143, No. 4. pp. 494-504.
@article{7ab695dfe09c451e9fa74a92bbdb1b44,
title = "Clinical utility of chromosome genomic array testing for unclassified and advanced-stage renal cell carcinomas",
abstract = "Context.-Cytogenomic analysis provides a useful adjunct to traditional pathology in the categorization of renal cell carcinomas (RCCs), particularly in morphologically ambiguous cases, but it has disadvantages, including cost. Objective.-To define the clinical scenarios in which this technology has direct clinical applications. Design.-DNA was isolated from paraffin-embedded tissue from 40 selected cases of RCC. Chromosome genomic array testing was performed using the OncoScan. Results.-Of 23 cases of unclassified renal tumors, 19 (83{\%}) were reclassified with incorporation of cytogenetic and histologic features, including 10 as clear cell RCC, 2 as collecting duct carcinoma, 2 as papillary RCC, and 1 as novel TFEB-amplified tumor lacking TFEB translocation. Of 5 tumors with ''hybrid'' oncocytic features, 3 were reclassified as an eosinophilic variant of chromophobe RCC and 1 as oncocytoma. Appropriate staging in 2 patients was determined by identifying distinct, nonshared cytogenetic profiles. Of 11 cases of metastatic clear cell RCC, 7 (63{\%}) had cytogenetic features associated with a poor prognosis. Conclusions.-We identified 5 scenarios in which chromosome genomic array testing has direct clinical utility: (1) to investigate unclassified RCCs, (2) to understand tumors with ''hybrid'' features and ''collision'' tumors, (3) to determine appropriate staging in questions of bilateral tumors and/or metastases, (4) to identify chromosomal aberrations in metastatic clear cell RCCs associated with a worse prognosis, and (5) to identify new entities. This has practical value in our institution, where a molecular profile diagnostically separating morphologically difficult to classify clear cell, papillary, chromophobe, and unclassified RCC influences treatment recommendations and clinical trial eligibility.",
author = "Nicole Andeen and Xiaoyu Qu and Tatjana Antic and Tykodi, {Scott S.} and Min Fang and Tretiakova, {Maria S.}",
year = "2019",
month = "4",
day = "1",
doi = "10.5858/arpa.2018-0104-OA",
language = "English (US)",
volume = "143",
pages = "494--504",
journal = "Archives of Pathology and Laboratory Medicine",
issn = "0003-9985",
publisher = "College of American Pathologists",
number = "4",

}

TY - JOUR

T1 - Clinical utility of chromosome genomic array testing for unclassified and advanced-stage renal cell carcinomas

AU - Andeen, Nicole

AU - Qu, Xiaoyu

AU - Antic, Tatjana

AU - Tykodi, Scott S.

AU - Fang, Min

AU - Tretiakova, Maria S.

PY - 2019/4/1

Y1 - 2019/4/1

N2 - Context.-Cytogenomic analysis provides a useful adjunct to traditional pathology in the categorization of renal cell carcinomas (RCCs), particularly in morphologically ambiguous cases, but it has disadvantages, including cost. Objective.-To define the clinical scenarios in which this technology has direct clinical applications. Design.-DNA was isolated from paraffin-embedded tissue from 40 selected cases of RCC. Chromosome genomic array testing was performed using the OncoScan. Results.-Of 23 cases of unclassified renal tumors, 19 (83%) were reclassified with incorporation of cytogenetic and histologic features, including 10 as clear cell RCC, 2 as collecting duct carcinoma, 2 as papillary RCC, and 1 as novel TFEB-amplified tumor lacking TFEB translocation. Of 5 tumors with ''hybrid'' oncocytic features, 3 were reclassified as an eosinophilic variant of chromophobe RCC and 1 as oncocytoma. Appropriate staging in 2 patients was determined by identifying distinct, nonshared cytogenetic profiles. Of 11 cases of metastatic clear cell RCC, 7 (63%) had cytogenetic features associated with a poor prognosis. Conclusions.-We identified 5 scenarios in which chromosome genomic array testing has direct clinical utility: (1) to investigate unclassified RCCs, (2) to understand tumors with ''hybrid'' features and ''collision'' tumors, (3) to determine appropriate staging in questions of bilateral tumors and/or metastases, (4) to identify chromosomal aberrations in metastatic clear cell RCCs associated with a worse prognosis, and (5) to identify new entities. This has practical value in our institution, where a molecular profile diagnostically separating morphologically difficult to classify clear cell, papillary, chromophobe, and unclassified RCC influences treatment recommendations and clinical trial eligibility.

AB - Context.-Cytogenomic analysis provides a useful adjunct to traditional pathology in the categorization of renal cell carcinomas (RCCs), particularly in morphologically ambiguous cases, but it has disadvantages, including cost. Objective.-To define the clinical scenarios in which this technology has direct clinical applications. Design.-DNA was isolated from paraffin-embedded tissue from 40 selected cases of RCC. Chromosome genomic array testing was performed using the OncoScan. Results.-Of 23 cases of unclassified renal tumors, 19 (83%) were reclassified with incorporation of cytogenetic and histologic features, including 10 as clear cell RCC, 2 as collecting duct carcinoma, 2 as papillary RCC, and 1 as novel TFEB-amplified tumor lacking TFEB translocation. Of 5 tumors with ''hybrid'' oncocytic features, 3 were reclassified as an eosinophilic variant of chromophobe RCC and 1 as oncocytoma. Appropriate staging in 2 patients was determined by identifying distinct, nonshared cytogenetic profiles. Of 11 cases of metastatic clear cell RCC, 7 (63%) had cytogenetic features associated with a poor prognosis. Conclusions.-We identified 5 scenarios in which chromosome genomic array testing has direct clinical utility: (1) to investigate unclassified RCCs, (2) to understand tumors with ''hybrid'' features and ''collision'' tumors, (3) to determine appropriate staging in questions of bilateral tumors and/or metastases, (4) to identify chromosomal aberrations in metastatic clear cell RCCs associated with a worse prognosis, and (5) to identify new entities. This has practical value in our institution, where a molecular profile diagnostically separating morphologically difficult to classify clear cell, papillary, chromophobe, and unclassified RCC influences treatment recommendations and clinical trial eligibility.

UR - http://www.scopus.com/inward/record.url?scp=85063972686&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85063972686&partnerID=8YFLogxK

U2 - 10.5858/arpa.2018-0104-OA

DO - 10.5858/arpa.2018-0104-OA

M3 - Article

VL - 143

SP - 494

EP - 504

JO - Archives of Pathology and Laboratory Medicine

JF - Archives of Pathology and Laboratory Medicine

SN - 0003-9985

IS - 4

ER -